Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT04398927 Withdrawn - Metastatic Cancer Clinical Trials

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(recommended from NCCN guideline), our previous study found better results from Folfirinox over GEMOX. Our current study were conducted for further investigation to verify the better method for metastatic ICC.

NCT ID: NCT04315246 Withdrawn - Solid Tumor, Adult Clinical Trials

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Start date: August 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.

NCT ID: NCT04280640 Withdrawn - Cancer Clinical Trials

Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes

Start date: June 2021
Phase:
Study type: Observational

The purpose of this prospective, non-randomized, single-center pilot exploratory study is to investigate whether established circulating tumor cell (CTC) cultures have a similar response to targeted therapy treatment as the in vivo (patients') disease.

NCT ID: NCT04274790 Withdrawn - Cancer of Colon Clinical Trials

Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer

FLUORIB
Start date: June 1, 2021
Phase:
Study type: Observational

Analyze the dynamics of incorporation of 5-fluorouracil into cancer cell ribosomes from liver metastases of patient with metastatic colon cancer.

NCT ID: NCT04109937 Withdrawn - Bone Metastases Clinical Trials

External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial

EXPLORE
Start date: October 2020
Phase: N/A
Study type: Interventional

The objective of the present study is to evaluate the effectiveness of post-operative radiation therapy in lower extremity bone metastases. This trial will compare the health outcomes of patients receiving radiation therapy after Orthopaedic surgery to patients who will not receive radiation therapy post-surgery. The primary objective of the study is to compare the need for a subsequent surgery at the same treatment site within 12 months of the initial surgery. Additionally, the need for radiation or re-irradiation, functional status, performance status, pain scores, radiologically detected local disease progression, and overall length of survival will be compared at clinical endpoints for the two study arms. It is hypothesized that those randomized to receive post-operative radiation therapy will less likely need a subsequent surgery within the 12 months after the primary surgical intervention. This may optimize the quality of life for this patient population.

NCT ID: NCT03974204 Withdrawn - Breast Cancer Clinical Trials

Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.

Start date: July 2019
Phase: N/A
Study type: Interventional

This is a multicenter, interventional, prospective study among breast cancer patients with a suspicion of metastatic meningitis. The current study aims to assess the use of proteomic profile issued from cerebrospinal fluid microvesicles for diagnosis of leptomeningeal metastases.

NCT ID: NCT03972046 Withdrawn - Melanoma (Skin) Clinical Trials

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Start date: June 24, 2019
Phase: Phase 2
Study type: Interventional

This study will investigate whether the use of talimogene laherparepvec (T-VEC) in combination with BRAF/MEK inhibitor will result in durable regional and distant recurrence free survival in the neoadjuvant setting for treatment of advanced nodal BRAF mutant melanoma.

NCT ID: NCT03802747 Withdrawn - Colorectal Cancer Clinical Trials

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Start date: August 2019
Phase: Phase 1
Study type: Interventional

This study is evaluating the combination of Y-90 radioembolization followed by SBRT with the immunotherapy drugs, durvalumab and tremelimumab, to improve disease control of liver metastases for patients with microsatellite stable colorectal cancer.

NCT ID: NCT03754140 Withdrawn - Melanoma Clinical Trials

Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases

INTRANS
Start date: May 20, 2020
Phase: Phase 2
Study type: Interventional

There is currently an urgent need for low cost and well tolerated intralesional agents for the management of in transit and cutaneous melanoma metastases that are unsuitable for, or resistant to, other therapies. This pilot study will determine whether intralesional injections of the sclerosant polidocanol into intransit and cutaneous melanoma lesions shows promise for efficacy, safety and ease of use that will enable this inexpensive and widely available agent to undergo further evaluation.

NCT ID: NCT03696485 Withdrawn - Clinical trials for Secondary Progressive Multiple Sclerosis (SPMS)

Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

Start date: February 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective, single center, open label, phase I/IIa escalating dose study. To evaluate the safety and efficacy of escalating doses of SCM-010 in subjects with SPMS.